Monosodium Urate Contributes to Retinal Inflammation and Progression of Diabetic Retinopathy

Area of Science:

• Ophthalmology
• Endocrinology
• Immunology

Background:

• Diabetic retinopathy (DR) is a leading cause of vision loss.
• The role of monosodium urate (MSU) in DR pathogenesis is not well understood.

Purpose of the Study:

• To investigate the contribution of MSU to the development of diabetic retinopathy.
• To explore the therapeutic potential of hypouricemic agents in managing DR.

Main Methods:

• Analysis of MSU, inflammatory markers, and xanthine oxidase in human retinas and vitreous from DR patients.
• Measurement of MSU, inflammatory markers, and oxidative stress in streptozotocin-induced diabetic rats (STZ-rats).
• Assessment of hypouricemic drugs (allopurinol, benzbromarone) effects on retinal inflammation, leukostasis, blood-barrier function, oxidative stress, and NLRP3 inflammasome in STZ-rats.

Main Results:

• Elevated MSU levels correlated with inflammation and xanthine oxidase in human DR retinas.
• STZ-rats showed increased MSU levels, inflammation, oxidative stress, and leukostasis.
• Hypouricemic drug treatment reduced inflammation, oxidative stress, leukostasis, and improved retinal blood-barrier function in STZ-rats.
• Drug treatment downregulated NLRP3 inflammasome components (NLRP3, TLR4, IL-1β).

Conclusions:

• MSU crystals play a significant role in diabetes-induced retinal inflammation and DR.
• Asymptomatic hyperuricemia may be a risk factor for DR induction and progression.
• Hypouricemic therapy holds potential for preventing or treating DR.